David Nurse Discusses Flow State and Purpose-Driven Performance on Health is a Skill Podcast with Todd Vande Hei
Nurse, known for his work with NBA players and Fortune 500 executives, broke down the 'flow code formula,' a structured process designed to help individuals access states of heightened focus and effortlessness. He emphasized that flow, often thought of as rare or random, can be trained through a repeatable sequence of visualization, breathwork, somatic activation, and spiritual connection.
Advertisement
'Flow is not just for athletes,' said Nurse. 'Anyone can access it. It's about reaching that 10-hertz brainwave state where focus and freedom meet.'
The two also explored the concept of epigenetics—how environment and belief influence gene expression—and discussed the formative role that childhood experiences, coaching, and self-image play in shaping one's future potential. Drawing from examples like Steph Curry and Steven Spielberg, Nurse outlined a 'greatness formula' involving natural attributes, exposure, mentorship, and insatiable drive.
Vande Hei shared personal stories from his own family and company, Stark, emphasizing how belief in one's ability to evolve is a crucial ingredient in long-term health and success. He noted that many people self-sabotage because they don't truly believe transformation is possible, a point Nurse echoed.
'If you don't know who you want to be, you won't become that person,' said Nurse. 'You need to act from a vision of the future you, not the past.'
The episode also covered:
The role of psychedelics and ketamine-assisted therapy in facilitating ego detachment and behavior change
The connection between prayer, stress reduction, and long-term physical health
How spirituality influences resilience and mental clarity
Resetting mindset through visualization, bilateral tapping, and cross-lateral movement
How purpose-driven action sustains motivation over time
The conversation concluded with reflections on why trauma often reconnects people to higher purpose and why prayer, gratitude, and release of control can enhance not just emotional well-being, but cellular health.
David Nurse can be found at davidnurse.com and on social platforms @davidnurseNBA. His podcast, The David Nurse Show, and books on mindset are available online.
Listen to the full episode on YouTube, Spotify, or Apple Podcasts.
About Health Is a Skill
Health is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark. Through expert interviews and solo episodes, the podcast explores the systems, tools, and daily practices that optimize health and longevity in the modern world.
Media Communications:
Inquiries: [email protected]
Attachment
David Nurse explains the science of flow and self-transformation through mindset and neuroplasticity
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights
Inclusion body myositis and ASyS identified as most underserved IIM subtypes amid widespread calls for faster, safer, steroid-sparing therapies. EXTON, PA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies (IIM)—including classic dermatomyositis (DM), polymyositis (PM), and clinically amyopathic dermatomyositis (CADM)—remain inadequately managed, according to new research from Spherix Global Insights. The latest Market Dynamix™: IIM (US) study, based on research conducted with 104 rheumatologists and six in-depth interviews, reveals persistent challenges in managing this complex and heterogenous group of rare autoimmune conditions, particularly for patients with DM and PM, which together make up the majority of IIM cases under rheumatologist care. Glucocorticoids remain the dominant first-line treatment across IIM subtypes, but their long-term use is widely viewed as problematic. Fewer than half of DM and PM patients—and just over half of those with CADM—are considered well-controlled on current regimens. Nearly all rheumatologists report turning to combination therapy to improve outcomes, with methotrexate most commonly added to glucocorticoids. Yet, few physicians express satisfaction with available options for DM and PM. Steroid minimization is a central, yet often elusive, goal—hampered by limited access to effective and targeted alternatives. CADM adds further complexity due to its dermatologic dominance and inconsistent response to immunosuppressants. Rare forms of IIM, including anti-synthetase syndrome (ASyS), necrotizing myopathy (NM), and inclusion body myositis (IBM), present even greater clinical complexity. These subtypes are often under-recognized, slow to diagnose, and highly refractory to existing treatments. IBM is rated the most challenging IIM subtype to manage, followed closely by ASyS and NM. Rheumatologists report that these conditions demand earlier, more aggressive intervention, often involving IVIg, rituximab, and combination DMARD strategies—especially when interstitial lung disease (ILD) or severe muscle involvement is present. Still, barriers related to diagnosis, insurance coverage, and the absence of disease-modifying agents are frequently reported. '[The] ability to treat patients with medication that specifically treats the disease overall rather than manifestations of the disease [is needed]—especially in those with pulmonary or cardiac manifestations,' one physician emphasized. 'Making the diagnosis is also challenging initially.' Looking ahead, rheumatologists are placing high hopes on emerging therapies in development, particularly those that could offer safe, rapid, and steroid-sparing disease control. AstraZeneca's Saphnelo (anifrolumab) leads in preference due to familiarity in lupus, a targeted mechanism, and strong efficacy data. Priovant Therapeutics' brepocitinib, a dual TYK2/JAK1 inhibitor delivered orally, is also highly favored for its potential convenience and broad anti-inflammatory reach. Other pipeline candidates generating excitement include argenx's efgartigimod, noted for its similarity to IVIg and potential to induce long-term remission; Pfizer's dazukibart, an interferon-targeting mAb with monthly IV dosing; and CD19-directed CAR T-cell therapies such as KYV-101(Kyverna Therapeutics), viewed as the most promising long-term innovation due to curative potential. Across all IIM subtypes, the demand for innovation is unmistakable. Rheumatologists emphasize the need for therapies with faster onset, broader disease targeting (muscle, skin, lung), and greater patient convenience, such as once-daily oral administration. With nearly half of IIM patients estimated to be candidates for advanced systemic therapies, the market is primed for disruption—particularly by agents that offer strong safety, durable efficacy, and a reduced reliance on corticosteroids. Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Andy Stankus, Rheumatology Franchise Head Spherix Global Insights 4848794284 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Gentuity LLC Announces Agreement to Collaborate with GE HealthCare to Expand Access to Advanced Intravascular Imaging Platform
SUDBURY, Mass., Aug. 7, 2025 /PRNewswire/ -- Gentuity LLC, a Massachusetts-based medical technology company specializing in next-generation intravascular imaging devices, today announced an agreement with GE HealthCare to collaborate on commercial activities. The collaboration is intended to enhance the availability, adoption, and functionality of highly complementary imaging solutions for interventional cardiology. As part of the agreement, Gentuity and GE HealthCare aim to jointly pursue co-marketing initiatives and technical integration of their respective technologies. GE HealthCare also plans to explore opportunities to expand access to Gentuity's innovative products through its own distribution network in the United States. These products include: High-Frequency OCT Imaging System: A mobile console powered by machine learning technology, offering rapid setup and detailed imaging capabilities. Vis-Rx® Prime Micro-Imaging Catheter: The world's smallest imaging catheter at 1.8F, designed for comprehensive vessel imaging before and after percutaneous coronary intervention (PCI) procedures. "We are thrilled at the opportunity to expand our relationship with GE HealthCare and look forward to bringing our advanced imaging solutions to a broader range of healthcare providers," said Desmond Adler, President of Gentuity. "Our industry best serves our physicians and patients when we thoughtfully combine complementary technologies in a way that amplifies their individual impact, and we see this collaboration as an important enabling step in that direction." Founded in 2015, Gentuity is an established leader in the development of advanced intravascular imaging technologies possessing excellent usability and performance. The company's proprietary platform integrates artificial intelligence tools and user-centric design to reduce operator burden with the goal of improving procedural success, extending the known clinical benefits and cost efficiencies of intravascular imaging to a broader range of patients. "At GE HealthCare, we strive to tell the story of the heart through technologies that help diagnose, treat and monitor cardiovascular conditions," said Jyoti Gera, CEO, CardioVascular and Interventional Solutions at GE HealthCare. "This joint initiative with Gentuity supports this mission and reflects our shared commitment to delivering high-quality medical devices that that enhance patient outcomes and quality of life." For more information about Gentuity's products and this agreement, please visit or contact info@ Forward-Looking Statements This release contains forward looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "aim," "estimate," "potential," "position," and similar expressions. These forward-looking statements may include, but are not limited to, statements about the collaboration, the anticipated outcomes of the collaboration, and any new products or solutions resulting from the collaboration or otherwise. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company's inability to achieve the anticipated benefits of this collaboration, business or commercial disruptions, and unexpected risks and liabilities impacting the Company. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. Media Contact: Gentuity LLCEmail: info@ +1 888-967-7628 About Gentuity LLC: Gentuity LLC is a medical technology company dedicated to developing next-generation intravascular imaging devices. Based in Sudbury, Massachusetts, Gentuity focuses on crossing new frontiers in cardiovascular care so patients can focus on living. View original content to download multimedia: SOURCE Gentuity, LLC
Yahoo
32 minutes ago
- Yahoo
mPulse Sees Accelerated Revenue Growth and Product Adoption in First Half of 2025
Rapid momentum was fueled by the Company's Health Experience and Insights (HXI) capabilities that are addressing core engagement challenges across the healthcare ecosystem LOS ANGELES, August 07, 2025--(BUSINESS WIRE)--mPulse, a leading provider of Health Experience and Insights (HXI) technology, today announced accelerated financial performance in the first half of 2025 driven by sales of multi-product solutions across its predictive analytics, omnichannel engagement and health portal products. mPulse's integrated solutions are being adopted by both large national and regional health plans and are driving strategic expansion and net new customer growth. mPulse's multi-product HXI solutions address key efficiency challenges and drive better outcomes across the health consumer journey. The company's unified member 360 data allows health plans to visualize the consumer journey with outcomes and engagement data that are automatically captured to enable closed-loop analytics and continuous optimization. mPulse's partnerships with over 400 healthcare organizations, including 40 of the 50 largest health plans, are driving innovation and enhanced product offerings. "The rapid adoption of mPulse's multi-product solutions by leading health plans is a clear indicator that HXI is addressing core challenges in the market," said Bob Farrell, CEO of mPulse. "Engagement programs are driving portal utilization so health plans are realizing much higher value from their technology investments. Our unified member 360 data is providing a single view across departments which dramatically streamlines processes and enables highly tailored member experiences." On the heels of its Q1 and Q2 2025 market momentum, mPulse was also recently recognized in Gartner® Hype Cycle™ for US Healthcare Payers, 2025 for the 4th year in a row across the Health Navigation Solutions and Digital Broker categories. The report focuses on payor technologies and deployment approaches that enable digital optimization of current business processes and transformational technologies that promise high strategic value. The mPulse team believes this inclusion as a Sample Vendor across categories to be an indicator of the broad value HXI capabilities deliver to support healthcare payors and their digital strategies. Amidst it's strong growth and recent industry recognition, mPulse also announced Activate2025, the industry's premier Health Experience and Insights conference for healthcare executives to learn, network, and celebrate innovative health engagement. This year's event, themed "Building Trust for Better Outcomes: Digital Strategies to Empower the Consumer Health Experience", will convene healthcare and technology thought leaders in Austin, Texas from September 23-24, 2025. The event will feature renowned keynote speakers, Chiquita Brooks-LaSure and Kate O'Neill, who will bring their decades of experience and expertise to event participants. Sessions will focus on connecting key member experience technologies, with specific tracks on technology solutions to drive performance across focus areas of the One Big Beautiful Bill including Medicaid work requirements and stricter enrollment and retention requirements for FFM plans. To see how mPulse can support your organization, visit our website here or for more information or to register for Activate2025, visit here. About Gartner Gartner, Hype Cycle for U.S. Healthcare Payers, 2025, Robert Potts, Connie Salgy, Austynn Eubank, 16 June 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About mPulse mPulse, a leader in digital solutions for the healthcare industry, is transforming consumer experiences to deliver better, more equitable health outcomes. By combining AI-powered analytics, omnichannel outreach and digital health navigation technology, mPulse creates personalized health journeys and provides advanced insights to power collaboration across the healthcare ecosystem. With over a decade of experience and 4 billion consumer touchpoints annually, mPulse is the trusted Health Experience and Insights (HXI) partner for over 400 healthcare organizations. To learn more, visit View source version on Contacts Olivia Mannionmpulse@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
